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interstitial fluid are the two major components that drain 
from the CNS to regional lymph nodes. CSF drains via 
lymphatic vessels and appears to carry antigen-presenting 
cells. Interstitial fluid from the CNS parenchyma, on the 
other hand, drains to lymph nodes via narrow and restricted 
basement membrane pathways within the walls of cerebral 
capillaries and arteries that do not allow traffic of antigen-
presenting cells. Lymphocytes targeting the CNS enter by 
a two-step process entailing receptor-mediated crossing of 
vascular endothelium and enzyme-mediated penetration of 
the glia limitans that covers the CNS. The contribution of 
the pathways into and out of the CNS as initiators or con-
tributors to neurological disorders, such as multiple scle-
rosis and Alzheimer’s disease, will be discussed. Further-
more, we propose a clear nomenclature allowing improved 
precision when describing the CNS-specific communica-
tion pathways with the immune system.
Keywords CNS · CSF · Interstitial fluid · Immune 
privilege · Lymphatic drainage · Blood–brain barrier · 
Antigen-presenting cells · Dendritic cells · Glia limitans: 
multiple sclerosis · Alzheimer’s disease
Abbreviations
APC  Antigen-presenting cell
BBB  Blood–brain barrier
CAA  Cerebral amyloid angiopathy
CNS  Central nervous system
CSF  Cerebrospinal fluid
DC  Dendritic cell
EAE  Experimental autoimmune encephalomyelitis
ECS  Extracellular space
ISF  Interstitial fluid
MS  Multiple sclerosis
SAS  Subarachnoid space
Abstract Immune privilege of the central nervous system 
(CNS) has been ascribed to the presence of a blood–brain 
barrier and the lack of lymphatic vessels within the CNS 
parenchyma. However, immune reactions occur within the 
CNS and it is clear that the CNS has a unique relationship 
with the immune system. Recent developments in high-res-
olution imaging techniques have prompted a reassessment 
of the relationships between the CNS and the immune sys-
tem. This review will take these developments into account 
in describing our present understanding of the anatomical 
connections of the CNS fluid drainage pathways towards 
regional lymph nodes and our current concept of immune 
cell trafficking into the CNS during immunosurveillance 
and neuroinflammation. Cerebrospinal fluid (CSF) and 
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Introduction
The central nervous system (CNS), comprising the brain, spi-
nal cord, and neural parts of the eye, has a unique relationship 
with the immune system that has been referred to as immune 
privilege. Support for the concept of immune privilege for 
the CNS arose from experiments by Shirai nearly 100 years 
ago in which foreign homologous tissues were grafted to the 
brain and survived for prolonged periods; the concept was 
further emphasised by Medawar in 1948 [29, 86]. Neverthe-
less, immunological reactions do occur within the CNS par-
ticularly in association with infections by microorganisms and 
with diseases, such as multiple sclerosis (MS), that have an 
autoimmune component. As a sequel to the grafting experi-
ments, it was shown that if the same allografts were subse-
quently grafted on to the skin, allografts in the brain were rap-
idly rejected [29, 86]. It appears, therefore, that immunization 
in peripheral tissues precipitates immunological rejection of 
foreign tissue in the CNS. The description of immune privi-
leged sites as those in which: “grafts transplanted to them are 
in some way partially or fully exempted from the normal rig-
ours imposed by their histocompatibility status” is a definition 
of a state of relative tolerance [12, 45]. One further point that 
has been emphasised is that immune privilege does not apply 
to the meninges and CSF spaces [45]. If foreign tissue grafted 
into the brain enters the ventricles, it is rejected [45, 85].
Except for penetrating injuries of the brain or spinal cord, 
microorganisms do not enter the CNS unless they have 
passed through peripheral tissues, such as lung, gut, skin, 
or nasal mucosa. Thus, T lymphocyte-mediated immune 
responses, such as those involved in the rejection of skin 
allografts, in the elimination of microorganisms and in auto-
immune disorders, may only occur in the CNS in individu-
als that have been initially immunised by antigen in periph-
eral tissues.Immunological reactions comprise two major 
components: an innate response and an adaptive response. 
For the CNS, the innate response within the parenchyma 
itself is mediated by yolk sac-derived myeloid cells dif-
ferentiating into resident microglia. When present, MHC 
class I and II molecules on the surfaces of cells constantly 
present antigen. In the absence of an infection, this is self-
antigen and thus contributes to tolerance. Expression of 
MHC class I and II molecules on microglial cells has been 
shown to be suppressed by the electrical activity of CNS 
neurons [94]. Disturbance of this activity during neurologi-
cal disorders combined with cytokine activation of micro-
glial cells leads to expression of MHC class I and class II 
molecules on their surfaces and subsequent presentation of 
antigen to receptive T lymphocytes [13, 70, 80]. The adap-
tive response depends upon the presentation of antigen to 
lymphocytes by antigen-presenting cells (APC). In addi-
tion, the leptomeningeal and perivascular compartments of 
the CNS harbour professional APC, such as macrophages 
and dendritic cells (DC), that, without activating signals, 
constitutively express MHC class I and class II molecules 
and constantly present self-antigens and thus may promote 
Box:Definions
1. Blood-brain barrier is used in two ways
i) Selecve passage of solutes through capillary endothelium into the CNS parenchyma. Breakdown 
of his barrier results in extravasaon of serum proteins and protein bound tracers from the blood 
into the CNS parenchyma.
ii) Receptor-mediated selecve adhesion and diapedesis of T lymphocytes through the endothelium 
of post-capillaries venules into the perivascular space. Further progress into the brain parenchyma 
requires MMP-dependent penetraon of the perivascular glia limitans.
2. Perivascular and paravascular
The term perivascular is used to denote pathways within the walls of capillaries, arterioles and 
arteries and spaces around postcapillary venules. Intramural perivascular pathways specifically refer 
to drainage routes along basement membranes between smooth muscle cells within the tunica 
media of arterioles and arteries.
Paravascular flow of CSF into the brain occurs along the outer aspects of cerebral arteries between 
the artery wall and the surrounding glia limitans.
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T-cell anergy. However, once activated, these APC have 
the potential to become the principal activators of T-cell 
responses in the CNS.
In tissues other than the CNS, activated APC migrate 
within well-defined lymphatic vessels to regional lymph 
nodes that present an environment specialised for antigen 
presentation in terms of anatomical and cell composition. 
Following the presentation of antigen, T and B lympho-
cytes proliferate to produce activated effector T cells and 
antibodies that return to the blood and to their target organs. 
Activated B cells also pass into the blood stream and then 
to bone marrow and may target tissues in which they can 
differentiate into plasma cells the CNS.
It has been proposed that immune privilege in the CNS 
is a result of two major factors: (a) the blood–brain barrier 
(BBB) (blood–CNS barrier) restricting entry of immune 
cells into the CNS and (b) the absence of the conventional 
lymphatics in the CNS. Both these factors will be discussed 
in the present review.
There are two major extracellular fluids within the cranial 
and spinal cavities associated with the CNS that could carry 
antigen or APC to regional lymph nodes, namely: cerebro-
spinal fluid (CSF) in the ventricles and subarachnoid spaces 
and interstitial fluid (ISF) in the extracellular spaces of the 
brain and spinal cord parenchyma. As will be outlined in this 
review, both CSF and ISF drain to cervical and lumbar lymph 
nodes, but there are significant differences between their 
drainage pathways (Fig. 1). CSF drains from the subarach-
noid space into lymphatic vessels in the nasal mucosa, in the 
dura mater, and into lymphatics associated with the sheaths 
of cranial and spinal nerve roots [11, 33, 69, 81]. The nasal 
and dural routes appear to allow the traffic of APC to lymph 
nodes [66, 81]; CSF compartments, (the ventricles and suba-
rachnoid space), do not exhibit the same immune privilege as 
the parenchyma of the CNS. In contrast to CSF, ISF drains 
from the brain parenchyma to cervical lymph nodes along 
very narrow, restricted pathways that comprise 100–150 nm-
thick basement membranes in the walls of cerebral capillar-
ies, arterioles, and arteries [24, 26] (Fig. 1). Such intramu-
ral perivascular basement membrane pathways are not large 
enough to allow the traffic of APC to regional lymph nodes 
and this may be a key factor in inducing immune privilege in 
the parenchyma of the CNS [24, 26].
In this review, we compare the connections between 
the CNS and the immune system with those of peripheral 
organs. The anatomical pathways and the physiology of 
lymphatic drainage of the CNS and how immune cells enter 
the CNS through the BBB are discussed in some detail. We 
examine the possible mechanisms involved in immunologi-
cal diseases of the CNS, how lymphatic drainage pathways 
are involved in the aetiology of Alzheimer’s disease and we 
also revisit the concept of immune privilege.
Lymphatic drainage of systemic organs other 
than the CNS
Lymphatic drainage into regional lymph nodes is normally 
involved in raising adaptive immunological responses in tis-
sues. ISF continuously extravasates from blood vessels and 
drains from tissues to lymph nodes. In most tissues of the 
body, except for the brain, spinal cord and parts of the eye, 
  Routes for drainage of CSF and ISF to cervical and lumbar 
lymph nodes 
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Fig. 1  Drainage pathways for CSF and interstitial fluid (ISF) to 
cervical lymph nodes. CSF and ISF drain to lymph nodes by differ-
ent and distinct pathways. In humans, CSF drains into the blood of 
venous sinuses through well-developed arachnoid villi and granula-
tions (AG). Lymphatic drainage of CSF occurs via nasal and dural 
lymphatics and along cranial and spinal nerve roots (outlined in 
green). Channels that pass from the subarachnoid space through the 
cribriform plate allow passage of CSF (green line) T cells and anti-
gen-presenting cells (APC) into nasal lymphatics (NL) and cervical 
lymph nodes (CLN). CSF from the lumbar subarachnoid space drains 
to lumbar lymph nodes. ISF from the brain parenchyma drains along 
basement membranes in the walls of cerebral capillaries and arter-
ies (blue arrows) to cervical lymph nodes adjacent to the internal 
carotid artery just below the base of the skull. This narrow intramu-
ral perivascular drainage pathway does not allow the traffic of APC. 
There is interchange between CSF and ISF (convective influx/glym-
phatic system), as CSF enters the surface of the brain alongside pen-
etrating arteries
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specialized lymphatic vessels begin as blind-ended capil-
laries and allow the free uptake of excess protein-rich ISF 
via discontinuous button-like junctions between lymphatic 
endothelial cells [6] (Fig. 2a). Once within the lymphatic 
vessels, tissue fluid is referred to as lymph. Lymph moves 
from the lymphatic capillary bed into pre-collector ves-
sels that connect to collecting lymphatic vessels (afferent 
lymphatics), as they drain lymph directly into the regional 
CSF Ag 
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Lymphac 
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Fig. 2  Pathways for lymphatic drainage of peripheral organs, CSF 
and cerebral interstitial fluid. a Tissue fluid from skin, gut, and other 
organs drains into blind-ended lymphatic vessels lined by endothe-
lium. Antigen-presenting cells (APC) also drain by this route to 
regional lymph nodes. Valves are shown in the lymphatic vessel. b 
CSF and antigen-presenting cells (APC) pass from the subarachnoid 
space through channels in the ethmoid bone, alongside olfactory 
nerves (ON), to enter lymphatics in the nasal mucosa and drain to 
cervical lymph nodes. CSF also drains via dural lymphatics towards 
the deep cervical lymph nodes (see text) c Interstitial fluid (ISF) 
from the brain parenchyma enters basement membranes in the walls 
of capillaries and then basement membranes between smooth mus-
cle cells in the tunica media of cerebral arterioles and arteries. The 
route of intramural perivascular drainage for ISF is indicated by blue 
arrows that track along the walls of intracranial arteries to cervical 
lymph nodes (CLN) related to the internal carotid artery at the base 
of the skull
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lymph nodes. While contractility of smooth muscle cells 
surrounding collecting lymphatic vessels and arterial pul-
sations ensure the forward movement of the lymph, valves 
of lymphatic endothelium prevent backflow of lymph. The 
lymph drains out of lymph nodes via efferent lymphatic 
vessels. In general, lymph nodes are arranged in series and 
the lymph eventually reaches two large lymphatic vessels, 
the thoracic duct and the right lymphatic duct that empty 
the lymph into the superior vena cava. Thus, the fluid is 
eventually transported back into the blood circulation and 
ensures tissue fluid homeostasis.
Lymphatic vessels have important functions for immune 
surveillance, as they transport antigens and activated APC, 
such as macrophages and DCs, from the peripheral tissues 
into the lymph nodes allowing adaptive immune responses 
to be mounted. Activated effector T and B cells and 
humoral factors, such as antibodies, are then delivered by 
lymphatic vessels into the blood stream.
When DCs residing in tissues take up foreign antigens, 
they become activated, a process that includes a loss of 
their tissue adhesive characteristics and upregulation of the 
chemokine receptor CCR7. These two factors induce the 
migration of DCs into lymphatic vessels by engaging the 
CCR7 ligand CCL21 specifically expressed by lymphatic 
endothelial cells. DCs first crawl along the lymphatic 
endothelium using specific adhesive interactions, e.g., the 
cytokine CCL21, before they detach and are passively 
transported to the regional lymph nodes in the larger cali-
bre lymphatic vessels [97, 115]. Once they have arrived in 
the lymph node, DCs activate antigen-specific T cells that 
in turn proliferate and reach the blood stream via the effer-
ent lymphatic vessels. The activation of B cells is mediated 
by the binding of soluble antigens to the B-cell receptors; 
in the case of protein antigens, they are internalized by DCs 
and presented to CD4+ T cells which in turn activate the B 
cells. Activated B cells and antibodies also reach the blood 
stream via efferent lymphatic vessels.
Interestingly, mouse models have provided evidence 
that some milieux in the body imprint immune cells to 
develop tissue-specific-trafficking programs. Environ-
mental cues from food (e.g., vitamin A) and sunlight (UV 
induced vitamin D3) are metabolized by DCs which allows 
them to imprint tissue-specific homing patterns in activated 
effector lymphocytes during the process of antigen pres-
entation [125]. Effector T cells produced in lymph nodes 
that drain the skin express the chemokine receptors CCR4 
and CCR10 and the cutaneous lymphocyte antigen, while 
effector T cells produced in lymph nodes that drain the gut 
express CCR9 and α4β7 integrin. This allows the different 
effector T-cell subsets to specifically home to the skin or to 
the gut once they are released back into the blood stream. 
Specific homing is achieved by the T cells engaging tissue-
specific vascular ligands (CCL27, CCL17, and E-selectin) 
(for skin) or CCL25 and MAdCAM-1 (mucosal cell adhe-
sion molecule −1) (for gut); these ligands are upregulated 
on the inflamed vascular endothelial cells in the skin or gut 
microvessels. Trafficking of lymphocytes to selected tissues 
provides a mechanism for segregating specialized adaptive 
immune responses to unique immune microenvironments. 
At least for the skin and the gut, DCs thus play a central 
role in this process, as, in addition to presenting antigens, 
they metabolize vitamins and respond to local tissue cues, 
including cytokines that they export to the regional lymph 
nodes.
Lymphatic drainage of the CNS
Of the two extracellular tissue fluids associated with the 
CNS, CSF is mainly located in the ventricles and subarach-
noid spaces and has a total volume in humans of 140 mL 
[19]. The other fluid is ISF in the extracellular spaces of the 
brain and spinal cord parenchyma and amounts to 280 mL 
in humans [19]. Both CSF and ISF drain to lymph nodes 
and are involved in immunological reactions within the 
CNS [34, 74, 106].
Lymphatic drainage of cerebrospinal fluid
CSF is mainly produced by the choroid plexuses in the 
cerebral ventricular system at the rate of 350 µL/min in 
humans [35]. A proportion of CSF may be derived from 
ISF [64]. Passing from the ventricular system into the suba-
rachnoid spaces, CSF in humans then drains partly into 
the blood via arachnoid villi and granulations in the walls 
of venous sinuses. A further proportion of CSF drains to 
regional lymph nodes via nasal lymphatics and dural lym-
phatics and via lymphatic vessels associated with cranial 
and spinal nerve roots [11, 33, 65, 69, 81] (Fig. 1). It is esti-
mated that at least 50 % of CSF drains into lymphatics in 
some mammals, [33] but the proportion in humans is still 
unknown [65].
The most prominent pathway for the lymphatic drainage 
of CSF is via channels that connect the subarachnoid space 
with lymphatic vessels in the nasal mucosa via the cribri-
form plate of the ethmoid bone (Fig. 2b). This pathway 
was demonstrated in humans in 1912 [148] and has more 
recently been confirmed in more detail in rats and other 
mammals, including humans [65, 69]. CSF from the spinal 
subarachnoid space drains to lumbar lymph nodes [69].
Two recent articles elegantly demonstrated functional 
lymphatic vessels in the dura mater of the mouse situated 
bilaterally along the superior sagittal sinus and draining 
through the cribriform plate into the nasal mucosa [11, 81]. 
Lymph vessels of the dura mater were probably described 
first by Mascagni in 1787 in his study “De lymphaticis 
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profundis capitis et colli” [21], and since then, functional 
drainage by this route has been demonstrated by Schwalbe 
et al. [121], Andres et al. [9], Cserr and Knopf [34], Kida 
et al. [69], and more recently by Aspelund et al. [11] and 
by Louveau et al. [81]. Although it has been suggested 
that lymphatic vessels in the dura drain fluid, solutes, and 
cells from the brain parenchyma, no such drainage has 
been demonstrated and the anatomical pathways for such 
drainage have not been demonstrated. It is more likely that 
dural lymphatics are one of the pathways for the drainage 
of CSF.
The capacity of the lymphatic drainage pathways for 
the CSF is reflected in experiments using particulate mat-
ter, such as Indian ink and Microfil [65, 69]. Several studies 
have also demonstrated efflux of T cells and APC from the 
CSF into deep cervical lymph nodes [47, 50, 51, 66, 101]. 
Moreover, myelin and axonal epitopes have been found in 
deep cervical lymph nodes after axonal injury and (auto-
immune) demyelination [36, 40, 79, 93]. Although it can 
be emphasised that APC may drain with CSF to lymph 
nodes by various routes, the migration of APC from brain 
parenchyma with ISF along narrow intramural periarte-
rial pathways is highly unlikely (see section on “Intramu-
ral perivascular drainage of ISF and solutes from the brain 
parenchyma”).
Current challenges thus include the clear identification 
of the anatomical routes by which APC traffic from the 
CSF and CNS parenchyma to deep cervical lymph nodes, 
and the unravelling of the role of antigen-presentation in 
neuroinflammatory and neurodegenerative diseases.
Drainage of interstitial fluid from the CNS parenchyma 
to regional lymph nodes
Experimental studies have shown that soluble tracers 
injected in minute amounts (0.5 μL) into the parenchyma 
of grey matter areas in the mouse brain initially diffuse 
through the extracellular spaces (ECS) and then rapidly 
enter the basement membranes of cerebral capillaries 
and drain directly via basement membranes in the tunica 
media of arterioles and arteries out of the brain to cervical 
lymph nodes [24, 26, 33] (Figs. 1, 2c, 3, 4). This intramural 
perivascular drainage route is outlined in the human brain 
by deposits of amyloid β (Aβ) in basement membranes in 
cerebral amyloid angiopathy (CAA) associated with age 
and with Alzheimer’s disease [25, 141]. Injection of larger 
volumes (2 μL) of tracer into the striatum of the mouse 
brain results in the passage of tracer into CSF in the ven-
tricles [15].
Origins of ISF
Water generated as a result of oxidation of glucose to CO2 
could provide a 10 % contribution to the total volume of 
ISF, but recently, it has been proposed that a large fraction 
of ISF is derived from the blood, passing through the capil-
lary endothelium and driven by Na, K ATPase with water 
following passively [2]. In addition to water, ISF consists 
of tissue metabolites and secreted proteins. The rate of bulk 
flow of ISF is estimated to be 0.1–0.3 µL min−1 g−1 in the 
rat brain [2]. Tracer experiments and mathematical models 
ISF and 
solutes 
PVM 
Arteriole Capillary Postcapillary  venule 
Tunica media Brain Parenchyma 
Ast 
Ast 
Glia limitans 
Fig. 3  Intramural perivascular drainage of interstitial fluid (ISF) out 
of the brain parenchyma. As an arteriole loses its tunica media, it 
becomes a capillary and then a post-capillary venule. Astrocyte end 
feet closely invests the surface of capillaries and form the glia limi-
tans. Capillary walls are the site of the blood–brain barrier (BBB) for 
solutes; the glial and endothelial components of the basement mem-
brane (green) are fused. The wall of the post-capillary venule is the 
BBB for lymphocytes and other inflammatory cells to cross from 
blood to CNS (see Fig. 6); the glial (blue) and endothelial (green) 
basement membranes are not fused. Interstitial fluid (ISF) and solutes 
drain from the extracellular spaces in the brain parenchyma through 
gaps between astrocyte end feet (yellow arrow) to enter bulk flow 
channels in basement membranes of cerebral capillaries. From there, 
ISF drains into basement membranes between smooth muscle cells 
in the tunica media of arterioles and arteries (yellow arrows): this is 
the intramural perivascular drainage pathway. Tracers following this 
pathway are taken up by smooth muscle cells in the tunica media and 
by perivascular macrophages (PVM) on the outer aspects of arterioles 
and arteries. Neither the endothelial basement membrane of arterioles 
and arteries (light blue) nor the outer basement membranes of the 
artery wall (green) are involved in the intramural perivascular drain-
age of ISF from the CNS
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show that ISF is eliminated from the brain by bulk flow 
along white matter fibre tracts and along perivascular path-
ways [32, 119].
Electron microscopy has shown that very narrow gaps 
separate the cells of the CNS, particularly in the grey mat-
ter [58, 91]. The gaps are interconnected and are filled 
with ISF; they represent the extracellular spaces (ECS) 
and are in direct continuity with the basement membranes 
of capillaries [89]. The most significant exchange between 
blood and CNS occurs at the capillary level. Cerebral cap-
illary endothelial cells are connected by highly complex 
and continuous tight junctions and form the BBB. While 
crossing the BBB requires specific transport systems, once 
beyond the BBB molecules diffuse over short distances of 
8–25 μm to the surrounding cells comprising the CNS. The 
movement of water mixed with the movement of soluble 
metabolites results in the flow of ISF [2, 3]. ISF drains 
from the ECS of the CNS parenchyma by entering capil-
lary basement membranes and then draining along the 
basement membranes of cerebral arteries by bulk flow, as 
indicated by physiological tracer experiments [24]. Bulk 
flow of ISF also occurs along the white matter fibre tracts 
[2]. Functionally, the ECS provides a pathway for the diffu-
sion and exchange of ions and molecules between cells; the 
movement of ISF through the ECS surrounding the cells of 
nervous system depends on diffusion [96, 130]. Diffusion 
through the ECS and bulk flow of ISF along perivascular 
drainage routes changes with age and in Alzheimer’s dis-
ease [54, 87].
Drainage of ISF along intramural perivascular 
pathways
Experimental studies in the 1980s by Cserr et al. first iden-
tified the perivascular route of drainage for ISF from the 
brain to cervical lymph nodes. These authors injected min-
ute amounts of radioiodinated serum albumin tracer into 
various regions of the rat brain and showed that the tracer 
drained to cervical lymph nodes along the walls of cer-
ebral arteries [33]. The speed of drainage to lymph nodes 
was comparable to that of lymphatic drainage elsewhere in 
the body. Only 10–15 % of tracer injected into the caudate 
nucleus or internal capsule passed into the CSF, although 
Blood Flow
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Fig. 4  Artery at the surface of the cerebral cortex. This figure shows 
the relationship of the artery with the subarachnoid space, the path-
way for entry of CSF into the brain, and the intramural perivascular 
pathway for the drainage of interstitial fluid (ISF) out of the brain. 
Blood flows along the lumen of the artery into the brain. The arterial 
endothelium (En) is separated from the tunica media (TM) by a base-
ment membrane (light blue), that is not involved in ISF transport, and 
by the extracellular matrix of the tunica intima. ISF and solutes flow 
out of the brain along basement membranes (brown) between smooth 
muscle cells in the tunica media. As tracers in the ISF flow along 
this pathway (yellow arrows), they are taken up by perivascular mac-
rophages (PVM—coloured yellow) and by smooth muscle cells in the 
tunica media. The pia mater forms a continuous layer of (blue col-
oured) cells; it coats the wall of the artery in the subarachnoid space, 
fuses with the pia mater on the surface of the brain, and extends as a 
layer of pia closely applied to the artery, as it enters the brain. CSF 
enters the brain from the subarachnoid space (the convective influx/
glymphatic pathway) along the basement membrane (dark blue) that 
is shared by the pia mater and the astrocytes of the glia limitans. In 
the normal cerebral cortex, there is no perivascular (Virchow–Robin) 
space around arteries, as they enter the brain. Tunica adventitia 
(TA) coats the leptomeningeal artery in the subarachnoid space, and 
perivascular macrophages (PVM) are aligned along the outer parts of 
the artery wall
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this figure was higher for tracer injected into the midbrain 
[131].
In this review, we will examine how the work of Cserr 
et al. has been expanded by the use of fluorescent tracers 
and confocal microscopy and how the perivascular drain-
age of ISF is relevant to neuroimmunology and to the 
pathogenesis of Alzheimer’s disease. Before examining the 
evidence for intramural perivascular clearance of ISF and 
solutes from the brain parenchyma, we will examine the 
structure of cerebral blood vessels and the vascular base-
ment membranes that form the pathways for perivascular 
drainage. Individually, blood vessels in the mouse brain 
have a similar basic structure to those in the human brain 
[76].
Capillaries
Capillary walls in the human and mouse brain are formed 
by an endothelium and a basement membrane, separating it 
from the brain ECS (Fig. 3) [91, 110]. While the junctions 
between adjacent endothelial cells form unique zonulae 
occludentes that inhibit paracellular diffusion of solutes, 
the high number of pericytes embedded in brain capillary 
basement membranes inhibits transcellular vesicular activ-
ity and thus transcellular diffusion of solutes [17]. Fibrous 
astrocytes form end feet that completely surround the cap-
illary surface: 40–100 nm separate the astrocyte end feet 
from the endothelium and this space is occupied by base-
ment membrane [38]. The layer of basement membrane 
produced by endothelial cells is distinct in its molecular 
structure from the basement membrane of the glia limitans 
produced by astrocytes, but the two basement membranes 
are fused. The capillary basement membrane is in direct 
communication with the brain extracellular spaces and 
encircles pericytes [142] that are responsible for the regu-
lation of capillary diameter and of cerebral blood flow in 
response to neural activity [16].
Arteries and arterioles
A normal cerebral artery on the surface of the brain (lep-
tomeningeal artery) has an endothelium separated from 
layers of smooth muscle cells by basement membrane, 
an intimal layer of extracellular matrix, and, frequently, 
an internal elastic lamina [138, 144]. As an artery enters 
the cerebral cortex, it loses its internal elastic lamina and 
its tunica adventitia to become an arteriole (Fig. 4). Base-
ment membranes are interposed between individual smooth 
muscle cells, and between the smooth muscle layers of the 
artery wall and its outer leptomeningeal sheath. The paren-
chymal basement membrane of the glia limitans separates 
the astrocyte end feet from the periarterial leptomeningeal 
sheath (Fig. 4). Smooth muscle cells within the artery wall 
possess contractile properties of fundamental importance 
for the regulation of cerebral blood flow. They are able to 
respond to mechanical (pressure), electrical, chemical, 
and hormonal stimuli [72]. The adhesion of the vascular 
smooth muscle cells to their basement membranes is essen-
tial for maintaining the integrity of the arterial wall and for 
recognizing and integrating the high variety of signals that 
modulate the cell function [126].
Studies of human brain show that leptomeningeal cells, 
identified by the presence of desmosomes and small nexus 
junctions, are reflected from the surface of the brain and 
spinal cord to coat arteries and veins in the SAS, thus sepa-
rating CSF in the subarachnoid space from the CNS and 
perivascular compartments [95, 137] (Fig. 4). Furthermore, 
leptomeningeal cells form a perivascular sheath around 
arteries, as they enter the brain. Periarterial compartments 
in the brain are separated from the subarachnoid space by 
pia mater (Fig. 4), but are in direct continuity with periar-
terial compartments of leptomeningeal vessels. Such com-
partments continue as basement membranes in the tunica 
media and as a layer of perivascular (adventitial) connec-
tive tissue coating arteries, as they pass through the base of 
the skull. Venous perivascular spaces communicate with the 
subpial space, as veins tend to lack a complete perivascular 
coat of leptomeningeal cells [146].
The pia mater prevents particles and erythrocytes [60] 
and, probably, neurotransmitters [41] in the CSF from 
entering perivascular compartments of the brain, but the 
exact degree of selective permeability to solutes of the pia 
mater and underlying glia limitans is not known. There 
are regional differences in the structure of arteries within 
the brain as shown by the enlarged perivascular spaces 
that develop with age around arteries in the basal ganglia 
[109] and white matter [140]; the perivascular spaces are 
enclosed by two layers of leptomeninges in these regions 
of the brain [109]. Arteries in the cortex, on the other hand, 
have only one layer of encompassing leptomeningeal cells 
and do not have perivascular space [146] (Fig. 4).
Vascular basement membranes are 100–150 nm-thick 
laminar matrices produced by endothelial, astroglia, smooth 
muscle cells, and pericytes [144] (Figs. 3, 4). In addition 
to providing a potential pathway for the clearance of sol-
utes out of the brain, the extracellular matrix, including the 
vascular basement membrane, determines the mechanical 
properties of the vessel wall and controls the migration 
and differentiation of vascular cells. In the brain, basement 
membranes have been reported to be secreted by meningeal 
cells and contribute to the migration and final positioning 
of neurons and to the differentiation of the laminar corti-
cal pattern during development [89]. Basement membranes 
are composed mainly of collagen type IV, laminins, nido-
gens, fibronectin, and heparan sulphate proteoglycans. The 
basement membrane is a dynamic complex, capable of 
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remodelling itself. In vitro, type IV collagen, laminin, and 
fibronectin are capable of assembly into a protein network 
resembling basement membranes and are interdependent in 
the formation of the basement membranes [145].
Intramural perivascular drainage of ISF and solutes 
from the brain parenchyma
To define the anatomical pathway for the bulk flow drain-
age of ISF and solutes from the brain parenchyma, minute 
quantities (0.5 μL) of fluorescent dextran 3KDa or oval-
bumin 49KDa were injected into the grey matter of the 
caudate putamen in the centre of the mouse cerebral hem-
isphere [24]. By 5 min after injection, tracers had spread 
diffusely through the ECS, but tracer was also present in 
the walls of blood vessels. Confocal microscopy showed 
that tracers were co-localized with laminin in the base-
ment membranes of capillaries and in the basement mem-
branes in the tunica media of arteries at time intervals of 
5–15 min after intracerebral injections into the caudate 
putamen [24] (Fig. 3). The location of the tracers in artery 
walls was very specific, as tracer was only in the basement 
membranes between the smooth muscle cells in the tunica 
media and not in the endothelial basement membranes or 
in the outer basement membrane encompassing the artery 
wall [24]. This defined the drainage route for ISF as an 
intramural perivascular pathway. In the normal brain, there 
are no actual “perivascular spaces” around arteries, as they 
enter the cerebral cortex (Fig. 4) [90, 137, 146]. The drain-
age route for ISF and solutes is along pathways within the 
tunica media of arteries and not along perivascular spaces 
(Fig. 2).
Some of the tracer, particularly 3KDa dextran, was taken 
up by a few smooth muscle cells in the tunica media and 
by perivascular macrophages on the outer aspects of the 
artery walls (Fig. 3). By 30 min after injection, the tracers 
had disappeared from the ECS of the brain and from the 
basement membranes in the walls of capillaries and arter-
ies, but tracers remained in the perivascular macrophages 
[24]. By 24 h after injection, the route taken by the tracers 
on their passage out of the brain was outlined by perivascu-
lar macrophages containing tracer and situated adjacent to 
intracerebral arteries and around leptomeningeal arteries on 
the surface of the brain [24].
The intramural perivascular drainage route is fast and 
specific to solutes and does not allow direct migration of 
APC from the CNS parenchyma to lymph nodes. When 
particles in the range of 15 nm–1 μm are injected into grey 
matter in the brain, they do not drain along intramural base-
ment membranes, but track along the outside of arteries and 
separate the glia limitans from the vessel walls [24, 147]. It 
was concluded from these studies that it was very unlikely 
that, due to their size, APC would be able to track along 
intramural arterial basement membranes from the brain to 
cervical lymph nodes [24].
Studies using radioiodinated serum albumin as a tracer 
suggest that once ISF and solutes have left the brain, they 
drain along the tunica media and the tunica adventitia of 
the major cerebral arteries, through the base of the skull to 
deep cervical lymph nodes [131] (Fig. 2c). The high lev-
els of radioactive tracer and Aβ in the walls of intracra-
nial arteries and the very low levels of tracer and Aβ in the 
walls of the carotid artery in the neck [123, 131] together 
with the presence of lymph nodes within the carotid sheath 
just below the base of the skull in humans strongly suggest 
that ISF and solutes leave artery walls in the neck to drain 
to adjacent cervical lymph nodes [30]. Quantitative stud-
ies of lymphatic drainage from the brain have shown that 
the speed of drainage is comparable to lymphatic drain-
age from other organs [131]. The quantity and volume of 
fluorescent tracers injected to outline the basement mem-
brane pathways for drainage of ISF from grey matter [24] 
are too small to be detected in the cervical lymph nodes. 
However, there is further evidence of drainage of solutes 
from the brain to cervical lymph nodes from transgenic 
mice that overexpress amyloid precursor protein and Aβ. In 
these mice, the amount of Aβ in the cervical lymph nodes 
reflects the degree of production of mutant Aβ in the brain 
parenchyma [105].
Impairment of intramural perivascular drainage
There is impairment in the clearance of soluble tracers 
along basement membranes with increasing age, hyper-
lipidaemia, and with possession of Apolipoprotein ε4 geno-
type (APOE4). Impairment is associated with age-related 
changes in the artery walls and biochemical changes in 
vascular basement membranes [52–55]. It is also possible 
to block the perivascular drainage pathways along arte-
rial basement membranes acutely as demonstrated by the 
impairment of drainage when Immune complexes lodge in 
arterial basement membranes [27]. Epigenetic modifica-
tions of the proteins that constitute the extracellular matrix 
appear to have a role in the properties of the cerebrovascu-
lar basement membranes [83] and may be involved in the 
impaired drainage of fluid and solutes from the brain asso-
ciated with hyperlipidaemia [53].
Accumulation of fluid in the cerebral white matter with 
age and Alzheimer’s disease in humans is detected as white 
matter hyperintensities (WMH) by MRI. One of the factors 
involved in the aetiology of WMH appears to be impaired 
drainage of fluid along intramural perivascular pathways 
in cerebral arteries affected by cerebral amyloid angiopa-
thy [140]. Similarly, the occurrence of amyloid-related 
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imaging abnormalities (ARIA) in the white matter of 
patients treated with Aβ immunotherapy for Alzheimer’s 
disease may be due to the increase in accumulation of Aβ 
in intramural perivascular drainage pathways as CAA, fol-
lowing the release of Aβ from the brain parenchyma [20].
Motive force for intramural perivascular drainage 
along cerebrovascular basement membranes
The observation that perivascular transport only occurs in 
living animals and ceases immediately after cardiac arrest 
suggests that pulsations in artery walls may generate the 
motive force for the transport of ISF and solutes out of 
the brain [24]. Furthermore, mathematical models indi-
cate that perivascular transport of ISF and solutes may be 
driven by the contrary (reflection) waves that follow each 
pulse wave [119]. The contrary wave travels in the reverse 
direction to the major pulse wave and in the reverse direc-
tion to the flow of blood. If the contrary wave does act as 
the motive force for the drainage of ISF and solutes, then 
the model dictates that some form of valve-like action is 
required to prevent reflux during the passage of the major 
pulse wave along the vessel wall [119]. As the route of 
drainage is within basement membranes [24], it is possible 
that the valve-like action results from changes in the ori-
entation of the molecules within the basement membranes 
[122]. As vessels age, they become arteriosclerotic, stiff, 
and less elastic, particularly in humans, and such stiffening 
may interfere with perivascular drainage of ISF and soluble 
metabolites in elderly individuals [59, 139].
Ischaemic stroke as well as amyloid accumulation 
results in a failure of perivascular clearance of solutes in 
the affected hemisphere [10]. Cerebral hypoperfusion in a 
mouse model of Alzheimer’s disease leads to accelerated 
accumulation of Aβ in the walls of leptomeningeal vessels 
and this can be reversed by phosphodiesterase inhibitor and 
vasodilator Cilostazol [102]. Thus, experimental evidence 
again suggests that the interplay between the strength 
of pulsations and vasomotion may be key to the efficient 
perivascular clearance along basement membranes.
Interrelationships between CSF and ISF: convective 
tracer influx/glymphatic system
CSF has been shown to circulate through the brain and mix 
with ISF. When horseradish peroxidase or fluorescent trac-
ers are infused into the cerebral CSF, they enter the surface 
of the brain along the outer aspects of penetrating arteries 
and mix with ISF in the ECS of the brain parenchyma [62, 
113]. Entry of tracers in the CSF into the brain is along 
basement membranes between the outer pial coating of 
the artery and glia limitans [91] (Fig. 4) and appears to be 
driven by arterial pulsations [62, 113]. Mixing of CSF with 
ISF is dependent upon the presence of astrocytic aquaporin 
4 [62]. Clearance of tracers that enter the brain from the 
CSF appears to be via paravenous flow either into the CSF 
or possibly to cervical lymph nodes [62]. The immunologi-
cal significance of the convective tracer influx/glymphatic 
system [62, 113] is unclear. Fluid and tissue metabolites 
in this system appear to drain back into the CSF and may 
reach lymph nodes via the CSF.
The convective tracer influx/glymphatic system is 
largely separate from the rapid, direct drainage of ISF from 
the brain parenchyma along the basement membranes in 
the walls of cerebral arteries (intramural perivascular drain-
age) to cervical lymph nodes (Fig. 4). The exact relation-
ship between the two systems, however, requires further 
investigation.
Pathways for the migration of antigen‑presenting 
cells from the CNS to regional lymph nodes
Dependent on dynamic local tissue conditions, the fates of 
leukocyte subsets migrating into the CNS parenchyma are 
fourfold: (1) transformation into another functional subset, 
e.g., adoptively transferred Th17 cells changing into Th1 
or IFN-gamma producing cells, or Th1* (IFN-gamma and 
IL-17 producing cells) or even Th2 cells [23], (2) eventual 
demise in situ and uptake by phagocytic cells, (3) long-
term residence, that is presumably rare, and (4) emigration 
to secondary lymphoid organs. Figures 1 and 2, together 
with the preceding sections in this review summarize cur-
rent views on cell migration pathways out of the brain.
The proportional contributions of the different pathways 
out of the brain and spinal cord are poorly understood. For 
instance, it is not fully understood why there is such a pre-
ponderance of drainage to deep cervical lymph nodes com-
pared to superficial cervical lymph nodes. It is also useful 
to draw attention here to the fact that cells carrying CNS 
components can also gain access to the spleen, through 
the blood. For example, a significant number of cells con-
taining proteolipid protein and a few cells bearing myelin 
basic protein are present in the red pulp and around vessels 
within the spleens of marmoset monkeys (Callithrix jac-
chus) suffering from experimental autoimmune encepha-
lomyelitis (EAE), an animal model for multiple sclerosis. 
In contrast, the spleens of adjuvant controls and untreated 
monkeys were almost completely devoid of cells contain-
ing myelin basic protein and proteolipid protein [36].
Much more is known about lymphatic drainage from the 
brain than from the spinal cord. Despite the fact that rodent 
EAE, produced by many induction protocols, is to a large 
extent a spinal cord disease, drainage to local lymph nodes 
remains largely unexplored. In the mouse, it seems obvi-
ous to assume that the lumbar lymph nodes drain the spinal 
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cord. In humans, with 500–700 lymph nodes in total, and 
many of them potentially receiving drainage from the spi-
nal cord, the identity of the draining nodes appears to be 
less clear. Using a chronic-relapsing EAE model in Biozzi 
ABH mice, van Zwam et al. [135] surgically removed 
a total of thirteen lymph nodes draining the CNS: eight 
superficial cervical lymph nodes (also called submandibu-
lar, facial, and jugular lymph nodes), two deep cervical 
lymph nodes (also called internal jugular lymph nodes), 
and the three lumbar lymph nodes (also called caudal of 
sacral or para-aortic lymph nodes). This led to a reduced 
severity of relapses and reduced spinal cord pathology. Fur-
tado et al. [44] had similar results upon extirpation of deep 
and superficial cervical lymph nodes in a transgenic spon-
taneous EAE model, as did Phillips et al. [106] in a cryole-
sion-enhanced model of cerebral EAE. These independent 
studies support the notion that lymph nodes draining the 
CNS contribute to disease pathology.
Tolerance
Although contributions of cervical lymph nodes to detri-
mental immunity in multiple sclerosis (MS) and EAE may 
seem rather obvious, it is important to point out that the 
cervical lymph nodes clearly can also mediate the induc-
tion of tolerance [88, 143]. For example, the injection of 
myelin basic protein into the CSF induces tolerance and 
prevents the subsequent induction of EAE [49]. Intrana-
sal administration of antigen also drives tolerance through 
superficial cervical and internal jugular lymph nodes [143].
It is entirely possible that the induction of tolerance ver-
sus generation of (auto)immune responses in lymph nodes 
draining the CNS occurs sequentially or even in parallel. 
We argue that this is played out at the level of the indi-
vidual T cell interacting with an individual APC dependent 
on the reciprocal quantitative and qualitative spectrum of 
signal 1 (MHC-peptide), signal 2 (panel of costimulatory 
and co-inhibitory receptors), and signal 3 (spectrum of sol-
uble cytokines). As reviewed by Card et al. [28], lymphatic 
endothelium can play active roles in regulating host immu-
nity. Secretion of immunosuppressive factors limits T-cell 
function and DC maturation. In addition, endothelial cells 
can directly drive T-cell tolerance by antigen presentation 
in the context of co-inhibitory ligands. Finally, lymphatic 
endothelium controls delivery of antigens in the lymph by 
scavenging and regulation of transendothelial transport. In 
the draining lymph node, immature DC in and lymph node 
stromal cells can present self-antigen to T cells in a tolero-
genic fashion.
Recent studies claim that in experimental stroke, auto-
immunity does develop after massive release of CNS anti-
gens, [133]. This follows up on studies by the same group 
demonstrating brain antigens in cervical lymph nodes of 
patients with stroke; there is some correlation between anti-
gen load, type, and clinical outcome [108]. Very little evi-
dence of MS or encephalitis has emerged following strokes,
Events in lymph nodes draining the CNS
Very recently, in back-to-back studies, the next genera-
tion sequencing was used to assess B-cell receptor reper-
toire in MS in peripheral blood versus CSF [104] and in 
brain versus cervical lymph nodes [82, 128]. Stern and 
colleagues [128] found B-cell populations with sequences 
closely resembling the germline, dubbed founder events, 
which were highly represented in both the CNS and cer-
vical lymph nodes. These are likely to undergo additional 
rounds of affinity maturation. The first antigen-dependent 
maturation of B cells would occur in the lymph nodes, as 
expected, but the lineage trees of the mutated clones sug-
gest that there is traffic in both directions and that affinity 
maturation can also take place in CNS-related compart-
ments, such as tertiary lymphoid structures in the menin-
ges. The data collectively suggest that there is bidirectional 
traffic between the CNS and cervical lymph nodes.
The surge of interest in contributions of the gut micro-
biome to risk and progression of MS has direct bearing on 
the cervical lymph nodes, with two prime examples from 
mouse EAE models. First, in a transgenic spontaneous 
EAE model driven by CD4+ T cells against MOG92-106, 
in which germfree conditions abolish disease induction, 
the cervical lymph nodes feature an ongoing MOG-specific 
germinal centre reaction [18]. Second, work from Lloyd 
and Dennis Kasper on how polysaccharide A from Bacte-
roides fragilis protects against EAE demonstrates increased 
numbers of regulatory T cells in cervical lymph nodes [98]. 
These studies underscore the importance of cervical lymph 
nodes for both T-cell and B-cell responses.
Efferent pathways between lymph nodes and the 
CNS
Activation of T cells that seek the CNS
The deep cervical and lumbar lymph nodes have been 
shown to a function as lymph nodes that drain the CNS 
[34]. Thus, effector T and B cells specifically targeting 
CNS antigens could well be activated in cervical and lum-
bar lymph nodes and might be imprinted there with CNS-
specific-trafficking programs similar to those described 
above for lymph nodes draining skin and gut, respectively.
Our current knowledge of the anatomical routes and 
molecular mechanisms involved in the trafficking of 
immune cells from secondary immune organs into the CNS 
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is mostly derived from studies in murine EAE, an animal 
model for MS that is focussed mainly on the spinal cord 
[39]. EAE can be induced by subcutaneous immunization 
of susceptible mice or rats with neuroantigens emulsified in 
adjuvants. In this case, autoreactive effector T cells that are 
normal constituents of the immune repertoire [103, 120] are 
activated in lymph nodes draining the skin. Alternatively, 
EAE can be induced by adoptive transfer; this entails the 
injection into susceptible recipients of neuroantigen-spe-
cific CD4+ T-cell blasts that have been activated in vitro. 
Previous studies have provided direct evidence for the 
migration of low numbers of encephalitogenic T-cell blast 
across the BBB in the spinal cord within several hours after 
transfer [56, 134]. However, recent studies performed in a 
Lewis rat model of EAE have shown that the majority of 
intravenously inoculated encephalitogenic T-cell blasts do 
not directly cross CNS microvessels, but rather accumulate 
in the lung [43, 100]. In the lung and its draining lymph 
nodes, the T-cell blasts were found to profoundly repro-
gram their gene expression profile, i.e., they upregulated a 
migratory program involving adhesion molecules, motility 
factors, and chemokine receptors, but down-regulated their 
activation program [100]. These newly-gained migratory 
properties enabled that these T cells to efficiently cross the 
BBB [13, 68]. Interestingly, encephalitogenic T cells were 
also shown to persist as long-lived memory cells within 
the lung tissue, where they could be stimulated to gain the 
competence to enter the CNS and trigger autoimmune dis-
ease within the CNS. Epidemiological studies suggest that 
infections of the respiratory tract play an important role in 
triggering relapses in MS, i.e., relapses in MS regularly fol-
low inflammation of the respiratory tract [124]. Therefore, 
it is quite conceivable that stimulatory environmental fac-
tors might directly elicit a pathogenic response of autoim-
mune T cells within the lung. These studies indicate that, in 
addition to the cervical lymph nodes and the gut [18], the 
lung can also serve as a location, where autoreactive T cells 
potentially become re-activated.
The three potential routes of entry for T cells into the 
CNS
The few studies that have directly addressed the early 
migratory steps of T cells into the CNS have mostly been 
performed in the framework of EAE and have suggested 
three potential routes of entry for encephalitogenic T cells 
into the CNS (reviewed in [39]) (Fig. 5).
1. Live cell-imaging studies have provided evidence 
for the migration of encephalitogenic CD4+ Th 1 
cells across leptomeningeal vessels associated with 
the spinal cord and the brain [13, 107, 134]. Migra-
tion is achieved by engaging constitutively expressed 
VCAM-1 on the BBB endothelium with activated 
α4β1-integrins expressed on the surface of the acti-
vated CD4+ Th1 cells [107, 134] (Fig. 5a).
2. Encephalitogenic T cells have also been shown to 
directly extravasate via the leptomeningeal microves-
sels into the subarachnoid space [13, 118] (Fig. 5b).
3. Encephalitogenic CD4+ Th17 cells that specifically 
express the chemokine receptor CCR6 would appear to 
initiate EAE by crossing the blood–CSF barrier in the 
choroid plexus by engaging CCL20, which is produced 
by choroid plexus epithelial cells, but not by endothe-
lial cells of the BBB [112]. With the ventricular CSF, 
the CD4+ Th17 cells seem to travel to the leptomenin-
geal (subarachnoid) spaces, where they accumulate and 
trigger neuroinflammation [111, 112] (Fig. 5c).
All three routes of entry for T cells share a peculiar-
ity that the cell invasion of the CNS parenchyma requires 
breaching of a second barrier, and thus, in total, the sequen-
tial breaching of two different tissue barriers (Fig. 5). As 
a first step, the effector T cells must migrate across any of 
the outer barriers, such as the endothelium of post-capillary 
venules (Fig. 6). As a second step, effector T cells must 
progress across the glia limitans that forms the layer of tis-
sue that surrounds microvessels in the CNS parenchyma 
and forms the surface of CNS apposed to the leptomenin-
ges and the subarachnoid space. Clinical EAE starts when 
inflammatory cells breach the glia limitans bordering the 
perivascular spaces or the surface of the brain or spinal 
cord. The molecular mechanisms mediating the migration 
across these two different barriers have not yet been clari-
fied in all their details, but they do include distinct molecu-
lar cues.
In healthy individuals, it is mostly central memory T 
cells and B cells and low numbers of innate immune cells 
that are detected in the CSF [7, 46, 71, 111]. This further 
underscores the ability of activated T and B cells to breach 
the outer brain barriers in the absence of neuroinflamma-
tion and perform immunosurveillance of the CNS by enter-
ing the CSF spaces.
Irrespective of having breached the endothelial BBB 
or the epithelial blood–CSF barrier, T cells will encounter 
APC that are resident in the CNS and strategically local-
ized in perivenular spaces and in CSF drained spaces right 
behind these brain barriers (summarized in [39, 111]). 
While the perivascular spaces around post-capillary ven-
ules harbour rare DCs [48], large numbers of macrophages 
are found in the subarachnoid spaces [13]. In addition, 
cells that express MHC class II (Kolmer or epiplexus cells) 
adhere as APC to the apical aspect of the choroid plexus 
epithelial cells that form the blood–CSF barrier [78]. In the 
framework of EAE, it has been shown that the recognition 
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of their cognate antigen on these APC is prerequisite for 
the subsequent migration of CD4+ T cells across the glia 
limitans into the CNS parenchyma to cause clinical EAE 
[13]. Direct evidence for this scenario has been derived 
from live cell-imaging studies of the spinal cord leptome-
ningeal spaces. The leptomeningeal vessels are embedded 
in a three-dimensional extracellular matrix network con-
sisting mainly of collagen fibres. T cells having crossed 
the blood–leptomeningeal barrier will encounter numer-
ous macrophages distributed within the leptomeningeal 3D 
milieu. These cells actively scan their environment with 
their cell processes [13]. Effector T cells migrating within 
the leptomeningeal environment are in regular contact with 
these cells that constitutively express MHC class II mol-
ecules on their membrane surfaces and thus are able to 
present myelin antigens to the pathogenic effector T cells 
[13, 70, 99]. In fact, live cell-imaging studies with activa-
tion-driven biosensors are able to demonstrate that T cells 
recognize their cognate antigen on these APC [80, 92] (the 
cognate antigen is the antigen that the T cell first encoun-
tered and which bound to its receptor and resulted in the 
cell proliferation and differentiation that generated the pop-
ulation of T cells sensitized to that antigen). The resulting 
antigen-specific activation of the T cells is not only of rel-
evance for the adherence of the T cells to the leptomenin-
geal milieu [118], but also for the consecutive expression of 
pro-inflammatory cytokine by the effector T cells that con-
stitutes a crucial signal for the initiation of the parenchy-
mal invasion of immune cells and the clinical autoimmune 
process [67]. The local T-cell activation triggers inflamma-
tory events that lead to the upregulation of additional adhe-
sion molecules and chemokines on endothelium at the BBB 
and epithelium at the blood–CSF barrier, thus, allowing the 
recruitment of additional circulating immune cells, includ-
ing DC and monocytes, across the brain barriers. Lack of 
T-cell activation by leptomeningeal macrophages will lead 
to T-cell detachment and their release into the CSF which 
flows largely driven by respiration rather than the cardiac 
cycle [37, 118] in this space.
Entry of T cells across inflamed brain barriers
Live cell-imaging studies have shown that the extravasation 
of circulating T cells across the inflamed BBB (activated 
by pro-inflammatory cytokines with high expression of 
ICAM-1, VCAM-1, and de-novo expression of P-selectin 
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Fig. 5  Three potential routes for entry of T-cells into the CNS. a 
Encephalitogenic T cells enter the CNS parenchyma by a first step, 
passing between (*) or through (**) the BBB endothelial cells of 
post-capillary venules into the perivascular space, where they need to 
see their cognate antigen on perivascular APC (triangle) before they 
penetrate the glia limitans as a second step (for details, see text and 
Fig. 6). b In EAE, T cells enter the CSF from leptomeningeal ven-
ules, where they need to see their cognate antigen on leptomeningeal 
macrophages (triangle) and might penetrate the pia mater and glia 
limitans to enter the CNS parenchyma; this route is less certain in 
MS (see text). c T cells pass from blood vessels into the stroma of 
the choroid plexus and may then penetrate the choroid plexus epithe-
lium to enter the ventricular CSF. They then pass into the subarach-
noid space (SAS) and may penetrate the CNS parenchyma by passing 
through the pia mater and the glia limitans in EAE; this route is less 
certain in MS (see text). Solid lines direct experimental evidence is 
available for this route; interrupted (dashed) lines indirect experimen-
tal evidence is available
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and other adhesion molecules) is mediated by a multi-step 
cascade starting with P-selectin glycoprotein-1 (PSGL-
1)-mediated T cell rolling on endothelial P-selectin [116] 
(Fig. 6). As T cells in the blood slow down, they recog-
nize, as yet unidentified, ligands on endothelial cells that 
bind to G-protein-coupled receptors on the T cells inducing 
“inside-out” activation of constitutively expressed integrins 
on the T-cell surface. Integrins are heterodimers constitu-
tively expressed on circulating immune cells in a “bend 
down conformation” that does not allow engagement with 
their ligands. Binding of a chemokine to its chemokine 
receptor triggers a downstream signalling cascade in the 
immune cell that eventually leads to what is referred to 
“inside-out” activation of the integrins which then engage 
talin and kindling; with this, the integrins on the outside 
of the cell change their conformation into an upright posi-
tion—now, the integrin can bind the ligand on the endothe-
lium. In mouse models of EAE, α4β1-integrin (VLA-4) 
mediates T-cell arrest on the inflamed BBB by interaction 
with endothelial VCAM-1. Subsequent polarization and 
extended crawling of the T cells against the direction of 
flow have been shown in vitro to be mediated by LFA-1 
interaction with endothelial ICAM-1 and ICAM-2 as in 
other vascular beds [1].
Crawling of encephalitogenic T cells against the direc-
tion of blood flow on the luminal side of spinal cord menin-
geal vessels in vivo has first been observed during the ini-
tiation phase of EAE in a Lewis rat EAE model [13]. In 
this case, T-cell adhesion to the endothelium and subse-
quent crawling was significantly reduced by blocking the 
function of α4β1-integrins, but not LFA-1 [13]. In addition, 
it has been proposed that the other adhesion molecules, 
such as ninjurin-1, ALCAM, and MCAM, participate in 
T-cell migration across the BBB [61]. A recent in vitro 
study showed that extensive crawling of encephalitogenic 
T cells against the blood flow is a unique characteristic 
when low levels of ICAM-1 are expressed on the BBB 
allowing the T cells to find sites for paracellular diapedesis 
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Fig. 6  Entry of encephalitogenic T cells directly into the CNS from 
the blood. A post-capillary venule in an inflamed brain showing the 
passage of T cells from the lumen into the CNS parenchyma in a two-
step process. Step 1 as a T cell passes from the capillary (T1) to the 
post-capillary venule, it rolls along the surface of the endothelium 
(T2) and is arrested by receptors on the T cell and endothelium (T3) 
(see text for details). The T cell leaves the lumen by diapedesis across 
the endothelial barrier (T4) and passes through the endothelial base-
ment membrane at sites containing α4 laminin. Areas of basement 
membrane containing α5 laminin do not allow such diapedesis. The 
T cell then enters the perivenular space (T5) formed by separation of 
elements of the glial-endothelial basement membrane (endothelial 
component: green; glial component: blue). At this point (T5), there is 
a step of “re-activation” by recognition of cognate Ag in the perivas-
cular space. As this step also occurs in the absence of neuroinflamma-
tion, this holds true for immune surveillance. Infiltrating T cells can 
recognize their cognate antigen on rare perivascular dendritic cells 
(DC) and on monocyte-macrophages (Mϕ). Step 2 of traffic from 
blood to CNS involves penetration of the basement membrane of the 
glia limitans (T6). Recognition of antigen leads to local T-cell activa-
tion and upregulation of further trafficking cues on the BBB endothe-
lium allowing for entry of additional immune cells, including bone 
marrow-derived macrophages and DCs, into the perivascular space. 
This leads to local expression of matrixmetalloproteinases (MMP) 2 
and 9 produced by macrophages (Mϕ) and to cleaving of extracellular 
matrix receptors of astrocytic end feet that allow inflammatory cells 
to enter the CNS parenchyma across the glia limitans (T7)
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[1]. Inflammatory stimuli increased the cell surface levels 
of ICAM-1 on the BBB endothelium, which abrogated 
extended T-cell crawling and allowed the T cells to cross 
the BBB via transcellular routes.
Role of α4‑integrins
Functional inhibition of α4-integrins completely abrogates 
T-cell entry into the CNS and thus inhibits clinical EAE. 
This contrasts with blocking P-selectin/PSGL-1 (rolling) 
and blocking LFA-1/ICAM-1/ICAM-2 (arrest) interactions, 
which fail to inhibit or only partially inhibit T-cell migra-
tion across the BBB. Similar mechanisms for trafficking 
across the BBB have also been shown for myeloid cells, 
including DC; this applies especially to the predominant 
role for α4-integrins [42, 63]. These findings have been 
translated to clinical use by treating relapsing-remitting MS 
with the humanized anti-α4-integrin antibody natalizumab 
[127].
Role of the glia limitans
As pointed out above, an important observation made in 
the EAE model is that as long as infiltrating T cells, and 
other inflammatory cells, reside in the perivascular spaces 
of post-capillary venules, and in the subarachnoid spaces, 
the animals do not develop any clinical signs of disease. 
Clinical EAE does require immune cells to traffic across 
the glia limitans. This next step involves TNF-α which trig-
gers expression of matrixmetalloproteinase-2 (MMP-2) and 
MMP-9 in perivascular and leptomeningeal myeloid cells 
leading to the cleavage of astrocyte dystroglycan which 
anchors the astrocyte foot processes to the parenchymal 
basement membrane of the glia limitans [4]. At the same 
time, the scavenger receptor CXCR7 is upregulated on the 
inflamed BBB endothelium leading to downregulation in 
the levels of the chemokine CXCL12 in the perivascular 
spaces which further facilitates mobilization of CXCR4+ T 
cells from the perivascular space into the CNS parenchyma 
[31]. In the CSF, CXCL12 acts as a homeostatic chemokine 
that maintains the expression of its ligand CXCR4 by 
immune cells, keeping them in the subarachnoid space; this 
may be relevant for immune surveillance.
In humans, the glia limitans on the surface of the CNS is 
much thicker than in rodents and consists of multiple lay-
ers of astrocyte processes [5]. Although lymphocytes and 
APC readily penetrate the delicate glia limitans around 
post-capillary venules in the human brain, the penetration 
of inflammatory cells through the thicker glia limitans on 
the surface of the brain and spinal cord is less certain. For 
example, plaques of demyelination on the surface of the 
cerebral cortex in MS may be associated with inflammatory 
cells in the overlying subarachnoid space [57]. However, 
the penetration of such cells across the glia limitans is not 
seen. The apposition of inflammatory cells in the CSF and 
demyelination in the cerebral cortex suggests that the dif-
fusion of soluble agents may either pass from CSF into 
brain [57], or agents, such as cytokines, may defuse from 
the brain into the CSF and attract inflammatory cells to the 
subarachnoid space [8].
Two‑step system for migration of immune cells into the 
CNS
Taken together, observations of immune cell migration into 
the CNS that are mainly derived from the EAE model have 
shown that the migration of lymphocytes into the CNS is 
tightly controlled by a system of at least two steps with 
an outer step at the level of the BBB and the blood–CSF 
barrier and an inner step at the level of the glia limitans 
(Fig. 6). The perivascular space or the subarachnoid space 
between these steps serve as checkpoints, in which the 
molecular keys required for immune cells to breach the glia 
limitans and to enter the CNS parenchyma are dependent 
upon local recognition of CNS antigens by the invading T 
cells [38].
CD8 T‑cell, B cell, and myeloid cell migration into the 
CNS
Although CD8 T cells contribute to immune surveillance 
of the CNS [22] and are key players in neuroinflamma-
tion [117], little is known about the cellular and molecular 
mechanisms involved in the migration of CD8 T cells into 
the CNS. Interaction between PSGL-1 and P-selectin has 
been shown to contribute to the recruitment of human CD8 
T cells in leptomeningeal brain vessels [14]. Recent devel-
opment of mouse models of CNS autoimmunity driven by 
CD8 T cells has led to the identification of the first molec-
ular mechanisms involved in cytotoxic CD8 T-cell migra-
tion into the CNS and has shown that these mechanisms 
are distinct from those used by CD4+ T cells. Although 
α4β1-integrin is essential for CD8 T-cell entry into the 
CNS in vivo, the vascular ligand engaged was identified 
as junctional adhesion molecule-B (JAM-B) rather then 
VCAM-1 used by CD4+ T cells [84]. A recent side by side 
comparison of CD8 versus CD4 T-cell migration across 
an in vitro model of the BBB further substantiated that 
molecular mechanisms mediating the multistep extravasa-
tion of CD8+ T cells across the BBB are distinguishable 
from those involved for CD4+ T cells [114] and thus need 
further investigation.
Even less is known about the molecular mechanisms 
guiding B cells and myeloid cells into the CNS during 
immune surveillance or neuroinflammation. Although 
α4β1-integrins contribute to B cell and myeloid cell entries 
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into the CNS [63, 77], the precise entry routes and molecu-
lar mechanisms involved in their multi-step recruitment 
across the brain barriers remain to be explored.
Relationships between lymphatic drainage of the 
brain and neurological disease
EAE and multiple sclerosis
A number of experiments using different models of EAE 
suggest the involvement of cervical or lumbar lymph nodes 
in neuroimmunological disease. Excision of the CNS-
draining lymph nodes in chronic-relapsing EAE reduced 
and delayed the burden of relapse and EAE pathology 
within the spinal cord. This finding suggests that specific 
responses to CNS antigens are initiated within lymph nodes 
that drain the CNS [135]. Further evidence comes from the 
cryolesion-enhanced form of cerebral EAE in which the 
removal of deep cervical lymph nodes during the incuba-
tion period of EAE and at the same time as the cerebral 
cryolesion significantly reduces the burden of EAE in the 
cerebral hemispheres [106]. Transfer of lymphocytes from 
animals with cryolesion-EAE resulted in EAE lesions 
that were predominantly in the cerebral hemispheres [73]. 
These results suggest that lymphocytes from donors with 
cryolesion-EAE target the brain in recipient animals in 
preference to the spinal cord. This might be due to tissue-
specific cues influencing the function of DC in the drain-
ing lymph nodes that allows them to imprint a CNS homing 
program that is different from EAE without a cryolesion. 
Enhancement and location of autoimmune inflammation in 
the brain following a focal cortical cryolesion injury ini-
tially involve chemokines, such as the macrophage chem-
oattractants CCL2 (MCP-1) and CCL12 (MCP-5), and the 
activities of afferent and efferent neuronal connections with 
the site of damage [129]. By analogy, similar factors may 
modulate or reactivate autoimmune inflammation in MS 
[129].
Induction of a CNS-specific inflammatory response is, 
however, slow. Experimentally induced death of oligoden-
drocytes in transgenic mouse models rapidly leads to strong 
activation of microglia-macrophages and accumulation of 
myelin components in lymph nodes that drain the CNS. 
However, the resulting infiltration of immune cells into the 
CNS does not occur until weeks after the insult [79, 132].
In MS, neuronal antigens were present in pro-inflam-
matory antigen-presenting cells in cervical lymph nodes, 
whereas the majority of cells containing myelin were anti-
inflammatory [136]. This may reflect a different origin of 
the cells or different drainage mechanisms. Indeed, cells 
containing neuronal antigens in human cervical lymph 
nodes did not express the lymph node homing receptor 
CCR7, whereas cells containing myelin antigens in situ 
and in vitro did. Nevertheless, cervical lymph nodes from 
CCR7-deficient mice affected by EAE contained the same 
amounts of myelin and neuronal antigens as wild-type 
mice. It was concluded from this study [136] that the type 
and frequencies of CNS antigens within the cervical lymph 
nodes are determined by the type and extent of CNS dam-
age. Furthermore, the presence of myelin and neuronal 
antigens in functionally distinct APC populations within 
MS cervical lymph nodes suggests that differential immune 
responses can be evoked.
There is no evidence from clinical experience in MS that 
cervical lymph nodes are enlarged or reactive, but this does 
not appear to have been pursued by systematic imaging 
[40]. However, there is great promise and opportunity in the 
development of advanced imaging methods both in experi-
mental animals, and in humans. So far, there has been very 
little effort to image lymph nodes that drain the CNS in MS 
patients, perhaps understandably since there is no overt evi-
dence for lymph node swelling. Progress in sonography, 
computed tomography, and magnetic resonance imaging 
could yield useful insights (reviewed in [75]), facilitated by 
the fact that cervical lymph nodes are relatively near to the 
skin. Novel imaging agents for brain compounds should be 
very informative for imaging the transport of soluble com-
pounds, such as, e.g., myelin fragments, lipids, and pro-
teins, molecules derived from axons and Aβ species. The 
ultimate aim would be in vivo labelling with probes suit-
able for clinical use and at a resolution that would allow 
imaging of single cells and soluble antigens. For instance, 
Aβ concentrated in basement membrane compartments, or 
myelin and axonal compounds in lymphatic vessels and 
in lymph node conduits could be labelled for detection by 
imaging techniques.
Cerebral amyloid angiopathy and Alzheimer’s disease
The brain has a unique and somewhat restricted pathway 
for the elimination of ISF and solutes from its parenchyma 
to cervical lymph nodes that serves not only an immuno-
logical function but is also a pathway for the elimination 
of soluble metabolites from the brain [25]. This system 
of elimination fails with age [54], and this appears to be 
a major factor in the aetiology of CAA and Alzheimer’s 
disease.
Amyloid-β (Aβ) is a peptide that can exist as soluble, 
oligomeric, insoluble, and β-pleated sheet fibrillar forms 
in the extracellular spaces of the brain parenchyma and in 
the walls of cerebral arteries and capillaries as CAA in the 
ageing human population and in Alzheimer’s disease. Aβ 
is derived from amyloid precursor protein and appears to 
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be produced by the majority of cells in the body, including 
the brain, throughout life. Elimination of Aβ from the brain 
entails absorption into the blood, degradation by enzymes, 
such as neprilysin, and drainage, along intramural perivas-
cular routes with ISF to lymph nodes [25]. With age and 
Alzheimer’s disease, insoluble fibrillary Aβ is deposited in 
intramural basement membranes of capillaries and arteries 
of the brain as CAA. Age-related changes in cerebral arter-
ies impair intramural perivascular drainage of ISF [54], 
and this may be a trigger for the amyloid cascade, loss of 
homeostasis and propagation of tau protein in the brain in 
Alzheimer’s disease [139].
Immune privilege
The original experiments demonstrating immune privilege 
in the brain showed that skin grafts directly implanted into 
the brain survived, but were rejected when similar grafts 
were placed on the skin [86]. However, if grafts extended 
into the ventricles and thus the CSF, they were rejected 
[86]. It has also been shown by several groups and more 
recently directly by live cell imaging that activated T cells 
can enter the CSF in the leptomeningeal spaces irrespec-
tive of their antigen-specificity; this closely resembles the 
routine immunosurveillance of tissues performed by T cells 
in organs other than the CNS [118]. These observations 
emphasise that, although there is immune privilege in the 
CNS, such privilege does not extend to the ventricles and 
leptomeningeal spaces that contain CSF.
Except for penetrating injuries of the brain or spinal 
cord, foreign material, including microorganisms, does not 
enter the CNS unless they have passed through peripheral 
tissues, such as lung, gut, skin, or nasal mucosa. Thus, it 
appears that T-cell-mediated immune responses, such as 
those involved in the rejection of skin allografts, in the 
elimination of microorganisms and in autoimmune disor-
ders, may occur in the CNS only if there has been initial 
immunization by antigen in peripheral tissues. There are 
also other factors that contribute to the unique interrela-
tionships between the CNS and the immune system. They 
include barriers to the entry of T cells and other inflamma-
tory cells into the CNS in addition to restricted pathways 
for APCs to traffic from the CNS parenchyma to lymph 
nodes; these barriers and pathways have been outlined in 
the review above.
In summary, the main factors that contribute to Immune 
Privilege of the CNS are:
1. The afferent intramural perivascular drainage path-
way for ISF from CNS parenchyma to regional lymph 
nodes is restricted to fluid and solutes and does not 
allow the traffic of APC. The only route for trafficking 
of APC to regional lymph nodes is by the lymphatic 
drainage of CSF.
2. There is no free diffusion of plasma filtrates across the 
blood–brain barrier or across the blood–CSF barrier 
into the CNS.
3. There is a blood–brain barrier and a blood–CSF barrier 
for the entry of lymphocytes and other inflammatory 
cells into the CNS. For lymphocytes, there is a two-
step process by which T cells first cross the post-capil-
lary venular endothelium by receptor-mediated mecha-
nisms and then a second step by which T cells cross the 
glia limitans. Such a restrictive pathway for the entry 
of T cells and other inflammatory cells is not seen in 
peripheral tissues. There is also restricted entry for 
polymorphonuclear leukocytes into the CNS; they are 
mostly seen in the CSF and in the CNS parenchyma in 
response to bacterial or fungal infections.
4. In contrast to the skin and other peripheral tissues, the 
CNS does not harbour resident T cells in the paren-
chyma, although they reside in ventricular and suba-
rachnoid compartments.
5. There is a lack of constitutive expression of MHC class 
II and class I in the parenchyma of the CNS which pro-
hibits antigen presentation in the absence of inflamma-
tory stimuli.
6. Microglial cells are a unique population of yolk sac-
derived tissue myeloid cells that migrate into the CNS 
during fetal development; they exhibit different func-
tions from APC in perivascular compartments of the 
CNS and in the CSF.
Conclusions
Recent advances in technology have increased our under-
standing of the relationship of the CNS to the immune 
system. This knowledge has been translated into the treat-
ment of relapsing-remitting MS with the humanized anti-
α4-integrin antibody natalizumab and to understanding 
perivascular pathways for the elimination of Aβ from 
the brain and their significance in Alzheimer’s disease, 
to give but two examples. However, our understanding is 
not complete. We look forward to further developments 
in advanced imaging techniques in experimental animals 
and also in humans to investigate migration of APC from 
CSF to lymph nodes. Progress in sonography, computed 
tomography, and MRI could yield useful insights into 
the physiology of cervical lymph nodes. Novel imaging 
agents for brain compounds could be developed to image 
the transport of soluble compounds from the brain along 
intramural perivascular drainage pathways to lymph nodes. 
This would aid the investigation of transport of cells and 
soluble antigens from the brain parenchyma and CSF in 
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neuroimmunological disorders. Evaluation of the age-
related failure of elimination of Aβ may lead to therapies to 
facilitate the elimination of Aβ from the brain in the man-
agement and prevention of Alzheimer’s disease.
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